HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

849.427

+11.2101.34%

Number of Gainers:13

Number of Losers:3

Number of Flat:2

PE:- -

High:855.333

Open:838.217

Low:835.921

Close:838.217

Loading ...

BRIEF-Sihuan Pharma Repurchased 10 Mln Shares At Average Price Of HK$0.6274 Per Share

Sihuan Pharma - Repurchased 10 Mln Shares at Average Price of HK$0.6274 per Share

THOMSON REUTERS

CSPC Pharmaceutical's Influenza Drug Gets China Nod for Registration

MT Newswires Live

CSPC Pharmaceutical - Oseltamivir Phosphate for Suspension Obtains Drug Registration Approval by Nmpa

THOMSON REUTERS

Shandong Xinhua Pharmaceutical Gets China Nod for Eszolam Marketing License Transfer

MT Newswires Live

Shanghai Fosun Pharmaceutical to Sell 55% Stake in Investment Firm

MT Newswires Live

BRIEF-CSPC Pharmaceutical Says SYS6041 Obtains Clinical Trial Approval In U.S.

Executive Chairman of CSPC Pharmaceutical Group Dongchen Cai Buys More Stock

Simply Wall St.

BRIEF-CSPC Pharmaceutical Says SYH2046 Tablets Obtains Clinical Trial Approval From NMPA China

CSPC Pharmaceutical Gets China Nod for Trial Of Cardiac Drug

MT Newswires Live

Baiyunshan Pharmaceutical's Unit Amends Production License

MT Newswires Live

Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial

MT Newswires Live

Sihuan Pharmaceutical Buys Back Shares

MT Newswires Live

Shares of BYD Electronic Jump More Than 14%

THOMSON REUTERS

BRIEF-Sihuan Pharma Intends To Exercise Its Powers Under General Mandate To Repurchase Shares Of Co

Sihuan Pharma - Intends to Exercise Its Powers Under General Mandate to Repurchase Shares of Company

THOMSON REUTERS

Sihuan Pharma - Repurchased 10 Mln Shares of Co at Average Price of HK$0.5866 per Share

THOMSON REUTERS

BRIEF-Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA

Sino Biopharmaceutical - Tqb3019 (Btk Protac) Approved for Clinical Trial by Nmpa

THOMSON REUTERS

China Traditional Chinese Medicine Controlling Shareholder Boosts Stake

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":849.42694,"timestamp":1744877287939,"preClose":838.21716,"halted":0,"volume":285547470,"delay":0,"changeRate":0.013373,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":11.209778,"latestTime":"04-17 16:00:00","open":838.21716,"high":855.3333,"low":835.9214,"amount":2158301222,"amplitude":0.023159,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"pbRate":1.548396,"peRate":20.662208,"turnoverRate":0.003749,"increases":13,"decrements":2,"flats":3,"marketCap":588493614656,"floatMarketCap":481284136192},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":855.3333,"amplitude":0.023159,"preClose":838.21716,"low":835.9214,"pbRate":"1.548396","latestPrice":849.42694,"volume":285547470,"delay":0,"open":838.21716,"prevYearClose":787.97723,"prevWeekClose":849.427,"prevMonthClose":870.015,"prevQuarterClose":870.015,"fiveDayClose":806.005,"twentyDayClose":952.56,"sixtyDayClose":746.059,"secType":"PLATE","market":"HK","turnoverRate":0.003749,"peRate":20.662208,"marketCap":588493614656,"floatMarketCap":481284136192,"timestamp":1744877287939,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":13,"down":3,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527288402","title":"BRIEF-Sihuan Pharma Repurchased 10 Mln Shares At Average Price Of HK$0.6274 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2527288402","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527288402?lang=en_us&edition=fundamental","pubTime":"2025-04-16 23:18","pubTimestamp":1744816681,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Repurchased 10 Mln Shares At Average Price Of HK$0.6274 Per ShareApril 16 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:REPURCHASED 10 MILLION SHARES AT AVERAGE PRICE OF HK$0.6274 PER SHAREFurther company coverage: 0460.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1515","00460","BK1191","BK1593"],"gpt_icon":0},{"id":"2527962852","title":"Sihuan Pharma - Repurchased 10 Mln Shares at Average Price of HK$0.6274 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2527962852","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527962852?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:40","pubTimestamp":1744800030,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1600","00460","BK1593","BK1191"],"gpt_icon":0},{"id":"2527416063","title":"CSPC Pharmaceutical's Influenza Drug Gets China Nod for Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2527416063","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527416063?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:54","pubTimestamp":1744721655,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical's  Oseltamivir Phosphate for Suspension obtained drug registration approval from China's National Medical Products Administration, a Tuesday filing with the Hong Kong bourse said.The move comes as the drug is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.Oseltamivir phosphate is indicated for the prevention and treatment of influenza A and B.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B5MMRT66.SGD","LU1226288253.USD","LU1008478684.HKD","IE0008369823.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","LU0072913022.USD","LU0326950275.SGD","LU1152091168.USD","LU1960683339.HKD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU1226287875.USD","LU0067412154.USD","LU0140636845.USD","LU1807302812.USD","BK1191","IE0008368742.USD","LU0880133367.SGD","BK1521","LU0501845795.SGD","LU1226287792.SGD","01093","IE00B543WZ88.USD","LU1226287529.USD","SG9999004220.SGD","BK1515","LU1951186391.HKD","LU1152091754.HKD"],"gpt_icon":0},{"id":"2527460193","title":"CSPC Pharmaceutical -  Oseltamivir Phosphate for Suspension Obtains Drug Registration Approval by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2527460193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527460193?lang=en_us&edition=fundamental","pubTime":"2025-04-15 18:07","pubTimestamp":1744711636,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT139:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1226287792.SGD","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1008478684.HKD","IE00B543WZ88.USD","LU1807302812.USD","LU0326950275.SGD","IE00BZ08YS42.EUR","LU0140636845.USD","LU1951186391.HKD","LU1960683339.HKD","LU0501845795.SGD","LU0067412154.USD","LU1226287529.USD","LU1226287875.USD","01093","IE0008369823.USD","IE00B031HY20.USD","BK1515","LU0072913022.USD","BK1521","IE0008368742.USD","LU1152091168.USD","BK1191","IE00BZ08YT58.USD","LU1993786604.SGD","LU1226288253.USD","LU1152091754.HKD","LU0880133367.SGD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2527945512","title":"Shandong Xinhua Pharmaceutical Gets China Nod for Eszolam Marketing License Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527945512?lang=en_us&edition=fundamental","pubTime":"2025-04-15 15:21","pubTimestamp":1744701700,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  has obtained approval for a change in the marketing licence holder of its Eszolam tablets from China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.The company had, in November 2022, entered into an agreement with Guangxi Dahai Sunshine Pharmaceutical, which agreed to transfer its Marketing Authorization Holder  status to the former for Eszolam.The drug is mainly used for anti-anxiety, insomnia or tension, fear, antiepileptics, and anti-convulsions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","00719","000756","BK7095","MAH.AU","BK1191","BK0164","BK0239"],"gpt_icon":0},{"id":"2527137940","title":"Shanghai Fosun Pharmaceutical to Sell 55% Stake in Investment Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2527137940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527137940?lang=en_us&edition=fundamental","pubTime":"2025-04-14 18:45","pubTimestamp":1744627530,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) agreed to sell a total equity stake of 55% in Shanghai Fujian Equity Investment Fund Management to three parties for around 26.5 million yu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK0187","BK0183","BK0012","02196","BK1515","BK0196","600196","BK0060","BK1593","BK0188","BK0239","BK0028","BK1191","00656","BK0175"],"gpt_icon":0},{"id":"2527135070","title":"BRIEF-CSPC Pharmaceutical Says SYS6041 Obtains Clinical Trial Approval In U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2527135070","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527135070?lang=en_us&edition=fundamental","pubTime":"2025-04-14 18:08","pubTimestamp":1744625334,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Says SYS6041 Obtains Clinical Trial Approval In U.S.April 14 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN U.S.Further company coverage: 1093.HK ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QR021:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU1226287792.SGD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1951186391.HKD","LU1993786604.SGD","01093","BK1515","LU1960683339.HKD","LU1226287875.USD","LU1226288170.HKD","BK1521","IE00B543WZ88.USD","LU1226287529.USD","LU0067412154.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1152091168.USD","LU0140636845.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU1226288253.USD","IE0008368742.USD","LU0326950275.SGD","LU1008478684.HKD","IE0008369823.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2526763620","title":"Executive Chairman of CSPC Pharmaceutical Group Dongchen Cai Buys More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2526763620","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526763620?lang=en_us&edition=fundamental","pubTime":"2025-04-12 08:39","pubTimestamp":1744418367,"startTime":"0","endTime":"0","summary":"Those following along with CSPC Pharmaceutical Group Limited ( HKG:1093 ) will no doubt be intrigued by the recent...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/executive-chairman-of-cspc-pharmaceutical-group-dongchen-cai","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1226287529.USD","LU1807302812.USD","01093","BK1515","IE00B543WZ88.USD","LU0326950275.SGD","LU1226287792.SGD","BK1191","LU0140636845.USD","LU1008478684.HKD","LU0067412154.USD","LU1226287875.USD","LU1960683339.HKD","IE0008368742.USD","IE00B031HY20.USD","LU1951186391.HKD","LU0880133367.SGD","LU0072913022.USD","LU1226288253.USD","LU1152091754.HKD","IE0008369823.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU1226288170.HKD","SG9999004220.SGD","BK1521","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2526691436","title":"BRIEF-CSPC Pharmaceutical Says SYH2046 Tablets Obtains Clinical Trial Approval From NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2526691436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526691436?lang=en_us&edition=fundamental","pubTime":"2025-04-11 23:08","pubTimestamp":1744384091,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Says SYH2046 Tablets Obtains Clinical Trial Approval From NMPA ChinaApril 11 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL FROM NMPA CHINAFurther company coverage: 1093.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QO1Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091754.HKD","IE00B543WZ88.USD","LU0326950275.SGD","LU1951186391.HKD","LU1993786604.SGD","LU1226288253.USD","LU1960683339.HKD","IE00B031HY20.USD","LU0140636845.USD","BK1515","LU1226288170.HKD","LU0880133367.SGD","LU1226287529.USD","SG9999004220.SGD","01093","BK1521","IE00BZ08YR35.GBP","LU0072913022.USD","LU1807302812.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU1152091168.USD","LU1226287792.SGD","IE00B5MMRT66.SGD","IE0008369823.USD","LU0501845795.SGD","LU1008478684.HKD","IE0008368742.USD","BK1191","LU0067412154.USD","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2526664155","title":"CSPC Pharmaceutical Gets China Nod for Trial Of Cardiac Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2526664155","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526664155?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:13","pubTimestamp":1744377230,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical (HKG:1093) obtained approval to conduct a clinical trial of its SYH2046 tablets in China from the country's National Medical Products Administration, a Friday filing with the Hong ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1807302812.USD","LU1226287529.USD","LU1152091168.USD","LU0326950275.SGD","01093","IE0008369823.USD","LU0067412154.USD","LU1951186391.HKD","LU1226287875.USD","BK1191","LU1226287792.SGD","IE00BZ08YS42.EUR","IE0008368742.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1152091754.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU1226288253.USD","LU0880133367.SGD","LU0072913022.USD","SG9999004220.SGD","LU0501845795.SGD","IE00BZ08YT58.USD","LU1008478684.HKD","BK1515","BK1521","LU1960683339.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0140636845.USD"],"gpt_icon":0},{"id":"2526553552","title":"Baiyunshan Pharmaceutical's Unit Amends Production License","url":"https://stock-news.laohu8.com/highlight/detail?id=2526553552","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526553552?lang=en_us&edition=fundamental","pubTime":"2025-04-10 18:08","pubTimestamp":1744279688,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600332","BK0070","BK1521","BK1606","BK0188","BK0028","BK1197","BK0183","BK0097","BK0096","BK0175","BK1191","BK1515","BK0196","00874","BK0239","BK0012"],"gpt_icon":0},{"id":"2526530013","title":"Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526530013","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526530013?lang=en_us&edition=fundamental","pubTime":"2025-04-10 17:56","pubTimestamp":1744278967,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  obtained clinical trial approval for its self-developed TQB3019  from China's National Medical Products Administration, a Wednesday filing with the Hong Kong bourse said.The drug is intended for use in the treatment of hematologic tumors, according to the biopharmaceutical firm.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","01177","BK1515","BK1521","BK1589"],"gpt_icon":0},{"id":"2526530555","title":"Sihuan Pharmaceutical Buys Back Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2526530555","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526530555?lang=en_us&edition=fundamental","pubTime":"2025-04-10 17:47","pubTimestamp":1744278472,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical  bought back 10 million shares from the market for nearly HK$5.9 million, or an average of HK$0.5866 apiece, a Wednesday filing with the Hong Kong bourse said.The shares represent roughly 0.1077% of the pharmaceutical company's issued share capital.The firm intends to hold the shares as treasury shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2526322201","title":"Shares of BYD Electronic  Jump More Than 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526322201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526322201?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:31","pubTimestamp":1744248709,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nL3N3QO05Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1504","BK1582","BK1589","BK1515","LU0274383008.USD","LU0348766576.USD","BK1149","BK1580","LU0348767384.USD","BK1607","BK1540","00285"],"gpt_icon":0},{"id":"2526991083","title":"BRIEF-Sihuan Pharma Intends To Exercise Its Powers Under General Mandate To Repurchase Shares Of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2526991083","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526991083?lang=en_us&edition=fundamental","pubTime":"2025-04-09 23:25","pubTimestamp":1744212335,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Intends To Exercise Its Powers Under General Mandate To Repurchase Shares Of CoApril 9  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:INTENDS TO EXERCISE ITS POWERS UNDER GENERAL MANDATE TO REPURCHASE SHARES OF COMPANYREPURCHASED 10 MILLION SHARES OF CO AT AVERAGE PRICE OF HK$0.5866 PER SHAREFurther company coverage: 0460.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","BK1600","00460","BK1593"],"gpt_icon":0},{"id":"2526735796","title":"Sihuan Pharma - Intends to Exercise Its Powers Under General Mandate to Repurchase Shares of Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2526735796","media":"THOMSON REUTERS","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526735796?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:25","pubTimestamp":1744197901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00460","BK1515","BK1600","BK1593","BK1191"],"gpt_icon":0},{"id":"2526335799","title":"Sihuan Pharma - Repurchased 10 Mln Shares of Co at Average Price of HK$0.5866 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2526335799","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526335799?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:25","pubTimestamp":1744197901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1191","BK1600","00460","BK1593"],"gpt_icon":0},{"id":"2526359258","title":"BRIEF-Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2526359258","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526359258?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:38","pubTimestamp":1744195128,"startTime":"0","endTime":"0","summary":"BRIEF-Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPAApril 9 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:TQB3019 (BTK PROTAC) APPROVED FOR CLINICAL TRIAL BY NMPAFurther company coverage: 1177.HK ((Reuter.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1589","BK1521","BK1191","01177"],"gpt_icon":0},{"id":"2526356894","title":"Sino Biopharmaceutical -  Tqb3019 (Btk Protac) Approved for Clinical Trial by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356894?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:14","pubTimestamp":1744193676,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","01177","BK1589","BK1515","BK1521"],"gpt_icon":0},{"id":"2526773338","title":"China Traditional Chinese Medicine Controlling Shareholder Boosts Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2526773338","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526773338?lang=en_us&edition=fundamental","pubTime":"2025-04-09 16:07","pubTimestamp":1744186052,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine  controlling shareholder China National Pharmaceutical Group or CNPGC purchased 50,350,000 shares at an average of HK$1.86 apiece, according to a Tuesday filing with the Hong Kong bourse.CNPGC holds 33.46% of China Traditional Chinese Medicine's entire stake as enlarged by the offering.Shares rose 1% during Wednesday's afternoon trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1606","00570","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}